Clinical trials: Psoriasis Patients
Psoriasis Vulgaris, Seborrheic Dermatitis
Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients
A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study.
- Conditions
- Psoriasis Vulgaris, Seborrheic Dermatitis, Microbial Colonization
- Trial name
- NCT03807453
- Testing
- Microbiota
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Medeniyet University
Psoriatic Arthritis
Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis
The aim of this study was to assess the effectiveness of resistance training in improving functional capacity, muscle strength, quality of life and disease activity in patients with PSA.
- Trial name
- PSA (NCT02598739)
- Testing
- Resistance exercise, Waiting list for the exercises
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Federal University of São Paulo
Insulin Sensitivity, Metabolism Disorder
Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis
The pathophysiological mechanisms explaining the association between psoriasis and type 2 diabetes are largely unknown but it has been hypothesized that systemic inflammation found in both psoriasis and type 2 diabetes might play…
- Trial name
- NCT02978001
- Testing
- Stabile Isotope tracers
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Arthritis, Psoriatic
Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions
A total of approximately 500 patients with active psoriatic arthritis in an estimated 80 to 100 trial centers are to be enrolled. Selection of centers will be made by the sponsor's medical section.
- Trial name
- LAPIS-PsA (NCT03106051)
- Where
- 2 sites in Germany
- Volunteers
- 526 people
- Sponsor
- Amgen
Psoriatic Plaque
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
- Trial name
- NCT04911751
- Testing
- KBL697
- Where
- 10 sites in United States, Australia
- Volunteers
- 80 people
- Sponsor
- KoBioLabs
Plaque Psoriasis
Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients
This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.
- Trial name
- NCT01301157
- Testing
- M518101, Dovonex
- Where
- 32 sites in United States
- Volunteers
- 294 people
- Sponsor
- Maruho Co., Ltd.
Demodicidosis
Association Between Biologic Therapy and Demodex Density in Psoriasis Patients: A Comparative Study
The goal of this observational study is to investigate whether the density of Demodex mites is higher in psoriasis patients treated with biologic agents compared to treatment-naive or topically treated patients.
- Trial name
- NCT05954572
- Testing
- standardized skin surface biopsy (SSSB)
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Hasan Aksoy
Psoriatic Arthritis
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
- Trial name
- NCT02267642
- Testing
- AbGn-168H
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Psoriasis
Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01018134
- Testing
- Desoximetasone 0.05% once daily, Desoximetasone 0.05% twice daily, Desoximetasone 0.25% once daily
- Where
- 7 sites in United States
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Hip Disease, Heart Failure
How Does Patients' Overall Assessment of Their Health Vary Across and Within Different Disease Groups?
EQ-5D is one of the most commonly employed patient-reported outcome (PRO) measures. It is included in many of the Swedish National Quality Registers (NQRs).
- Conditions
- Hip Disease, Heart Failure, Psoriasis, Fractures, Bone
- Trial name
- SWEQR (NCT04359628)
- Where
- Sweden
- Volunteers
- 700,000 people
- Sponsor
- Vastra Gotaland Region
Moderate to Severe Plaque Psoriasis
An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
BCD-085 is an innovative drug, a monoclonal antibody against interleukin-17. The toxicity, safety, and pharmacokinetics of BCD-085 were investigated in animals, in phase I clinical study in healthy volunteers, and in phase III…
- Trial name
- BCD-085-7 (NCT03390101)
- Testing
- BCD-085 Q2W, BCD-085 Q4W
- Where
- Russia
- Volunteers
- 213 people
- Sponsor
- Biocad
Psoriasis Patients, COVID-19
COVID-19 Associated With Psoriasis
A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.
- Trial name
- NCT05961605
- Where
- 12 sites in China
- Volunteers
- 2,500 people
- Sponsor
- Gang Wang, MD
Psoriasis
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
- Trial name
- PROGRESS-RO (NCT07582783)
- Where
- 20 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Primary objective of this study is to compare patient satisfaction with the prefilled syringe (PFS) and the auto-injector (AI), two different delivery devices for etanercept after 12 weeks of use, using a 10 point scale form…
- Trial name
- NCT00482170
- Testing
- Enbrel (etanercept), Etanercept
- Where
- 78 sites in Belgium, Denmark and 10 more
- Volunteers
- 421 people
- Sponsor
- Pfizer
Psoriasis
Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen
This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).
- Trial name
- NCT02097173
- Testing
- Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- medac GmbH
Generalized Pustular Psoriasis
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study.
- Trial name
- NCT04399837
- Testing
- Spesolimab
- Where
- 72 sites in United States, Argentina and 21 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
- Trial name
- NCT02933502
- Testing
- DSXS topical product
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
- Trial name
- NCT02684370
- Testing
- risankizumab, ustekinumab
- Volunteers
- 560 people
- Sponsor
- AbbVie
Psoriasis
Regulatory T-cells in Psoriasis Patients as Targets for Therapy
The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher…
- Trial name
- NCT01233583
- Testing
- Dovobet, neotigason, etanercept, adalimumab. infliximab
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Psoriasis
Alefacept Mechanism of Action in Psoriasis
To determine the mechanism of action of alefacept in patients with psoriasis.
- Trial name
- NCT00150982
- Testing
- Mechanism of action of alefacept
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.